News ReleaseView printer-friendly version
Quidel Corporation Appoints Renowned Experts in Reproductive Health to Advisory Board; Erudite Panel Rounds out Company's Clinical Expertise
SAN DIEGO, Aug 01, 2005 (BUSINESS WIRE) -- Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care diagnostic tests, has assembled a distinguished panel of researchers and clinicians to serve on the company's newly formed Reproductive Health Advisory Board. Well-known in the field of reproductive health, the expert panel will lend its vast collective experience and knowledge to assist Quidel in gaining greater insight into industry issues, as well as aid Quidel's development of new rapid diagnostic solutions that focus on reproductive health.
In addition to women's health issues, such as infectious vaginitis and sexually transmitted diseases, the panel's expertise extends to other important fields of bone health and oncology. The board will initially be charged with a review of Quidel's current reproductive health portfolio to determine if there could be other applications for existing products, in addition to gaining greater insight into market opportunities for future product development. Additional goals include helping Quidel identify and support relevant clinical research efforts.
"We are honored that these illustrious experts see the value of our Reproductive Health Advisory Board and are investing the time and commitment to advance the development and adoption of rapid diagnostic solutions in this important area of healthcare," said Caren Mason, president and chief executive officer of Quidel Corporation. "As ambassadors in the field of reproductive health, the panel will also provide valuable insight into clinicians' attitudes towards point-of-care testing in general, and, more specifically, provide input and expertise as we work to expand our portfolio of products to provide solutions that address the full spectrum of care both in infectious disease and reproductive health."
Chaired by David Soper, M.D. from the Medical University of South Carolina, the board also includes:
-- Daron G. Ferris, M.D., Medical College of Georgia
-- Megan Gerber, M.D., MPH, Harvard Medical School
-- Patti Gravitt, Ph.D., Bloomberg School of Public Health, Johns Hopkins University
-- Sharon Hillier, Ph.D., Magee-Women's Hospital, University of Pittsburgh
-- Mary Jacobsen, M.D., Stanford University Medical Center
-- Jeanne Marrazzo, M.D., MPH, University of Washington
-- Frank Miller, M.D., University of Kentucky, past president of ACOG
-- Paul Nyirjesy, M.D., Drexel University College of Medicine
-- Jane Schwebke, M.D., University of Alabama at Birmingham
-- Rosemary "Mimi" Clarke Secor, nurse practitioner, The Center For Women's Health
-- Jack D. Sobel, M.D., Detroit Medical Center
-- Harold Wiesenfeld, M.D., University of Pittsburgh
-- Jonathan M. Zenilman, M.D., Johns Hopkins School of Medicine
About Quidel Corp.
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), the portfolio currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration ("FDA"), intellectual property, product liability, environmental or other litigation, and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
SOURCE: Quidel Corporation
FischerHealth Cathy Diramio, 310-577-7870 x129 email@example.com